The 2026 LiBBY trial does not establish routine THC-CBD care for mild cognitive impairment (MCI). LiBBY means Life's End Benefits of cannaBidiol and tetrahYdrocannabinol, and it studied late-stage dementia agitation, not MCI.
THC is tetrahydrocannabinol, the intoxicating part of cannabis, and CBD is cannabidiol, a non-intoxicating part. The trial compared a purified THC-CBD oil with placebo, an inactive look-alike, for 12 weeks. For people with MCI, the relevant choice is whether to join future research, not to seek routine use.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who was in the LiBBY trial?
- What changed with treatment?
- Why doesn't this mean routine MCI treatment?
- What should you ask before joining a study?
Who was in the LiBBY trial?
The trial enrolled 120 hospice-eligible people with Alzheimer's or other dementia and clinically significant agitation. Agitation here means restlessness, verbal aggression, or physical behaviors that disrupt comfort and safety. The Alzheimer's Association AAIC release describes this 12-week Phase 2 randomized, double-blind, placebo-controlled test details of the AAIC presentation. Participants received 2 mg THC plus 100 mg CBD twice daily or matching placebo, according to Pennington Biomedical.
Study visits occurred at homes or residences across 9-10 U.S. sites. Phase 2 means an early controlled efficacy test, while randomized and double-blind means chance assigned treatment and neither patients nor staff knew the assignment. The study enrolled only hospice-eligible late-stage dementia with agitation. It did not enroll people with MCI and did not test slowing MCI, according to the federal trial eligibility listing.
What changed with treatment?
Treated patients had 6.27 points greater agitation-score reduction than placebo at week 2 and 8.23 points greater at week 12. Labroots reporting on the AAIC presentation describes these as agitation-symptom differences report on the AAIC presentation. That means less frequent or severe agitation behaviors during the study period.
It does not mean better memory, clearer thinking, or slower movement from MCI to dementia. A separate 2026 Washington State University study, summarized by MedicalXpress, tested vaporized THC at 20 mg or 40 mg in 120 cannabis users. It found broad impairment of verbal, visuospatial, prospective, source, and temporal-order memory. Memory harm from intoxicating THC matters when weighing any brain-health decision.
Why doesn't this mean routine MCI treatment?
Overall adverse-event rates looked similar between groups in LiBBY. Still, 120 patients followed for 12 weeks near end of life is too small and brief to establish routine safety for healthier people with MCI, according to the NIA-funded ACTC summary via News-Medical.
The tested oil is also not FDA-approved for dementia agitation. McKnight's reporting in July 2026 identifies the specifically approved options cited that year as brexpiprazole from 2023 and dextromethorphan-bupropion, sold as Auvelity, from early 2026.
What should you ask before joining a study?
The National Institute on Aging advises people with MCI to contact study staff and discuss practical details before enrolling NIA guidance on participating in research. Use these questions at screening to compare studies and protect daily care.
Bring your medication list and visit schedule to the screening call. Ask the study team to note which answers apply to you and share them with your regular clinician.
- Will I possibly receive placebo, and how will I be monitored?
- What benefits and risks are possible for someone with MCI?
- How many visits, tests, and travel hours does participation require?
- What costs, payment, or insurance issues could arise?
- Should I discuss enrollment with my regular clinician first?
You Might Also Like
- Why the 2026 LiBBY Trial Does Not Establish Routine THC-CBD Care: A Source-Checked Research Briefing for People With Mild Cognitive Impairment
- Physical Activity in the 2026 WHO Dementia Guideline: What People With Mild Cognitive Impairment Can Track Without Self-Diagnosing
- Why the AAIC 2026 Soccer Study Does Not Prove Dementia: Research Participation Questions for Family Caregivers
